HIV-1 Infection - Pipeline Review, H1 2015
M2 - Wed May 13, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrjl97/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CompleGen, Inc. - Critical Outcome Technologies Inc. - CytoDyn Inc. - Enzo Biochem, Inc. - FIT Biotech Oy - GeneCure LLC - Gilead Sciences, Inc. - GlaxoSmithKline plc - Heat Biologics, Inc. - InnaVirVax SA - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Merck & Co., Inc. - Mymetics Corporation - Myrexis, Inc. - Oncovir, Inc. - OyaGen Inc. - Peregrine Pharmaceuticals, Inc. - Pfizer Inc. - Pharis Biotec GmbH - United Biomedical, Inc. - Valens Therapeutics, Inc. - Vichem Chemie Research Ltd. - ViiV Healthcare Limited For more information visit http://www.researchandmarkets.com/research/wr..._infection
HTBX: 5.77 (-0.40), PFE: 33.99 (+0.05), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ARGS: 7.68 (+0.09), INO: 7.97 (-0.02), JNJ: 102.30 (+0.47), ENZ: 2.50 (unch), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45)